An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
暂无分享,去创建一个
[1] I. Fukui,et al. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. , 1994, The Journal of urology.
[2] O. Dalesio,et al. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. , 1982, European urology.
[3] H. T. Herring. THE TREATMENT OF VESICAL PAPILLOMA BY INJECTIONS , 1903, British medical journal.
[4] Richard Sylvester,et al. Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .
[5] Thomas D. Schmittgen,et al. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. , 1994, The Journal of urology.
[6] P. Nieh,et al. A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa. , 1979, The Journal of urology.
[7] W. Frable,et al. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. , 1981, The Journal of urology.
[8] M. Soloway,et al. Thiotepa-induced myelosuppression: review of 670 bladder instillations. , 1983, The Journal of urology.
[9] M. Parmar,et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. , 1996, The Journal of urology.
[10] B. Ali-El-Dein,et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. , 1997, The Journal of urology.
[11] R. Bahnson,et al. Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder , 1997 .
[12] U. Nseyo,et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. , 1995, The Journal of urology.
[13] W. Lutzeyer,et al. Natural history and treatment of low and high risk superficial bladder tumors. , 1988, The Journal of urology.
[14] Sarosdy Mf. Principles of intravesical chemotherapy and immunotherapy. , 1992 .
[15] E. Solsona,et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. , 1999, The Journal of urology.
[16] K. Burnand,et al. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. , 1976, British journal of urology.
[17] F. Schröder,et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. , 1997, The Journal of urology.
[18] S. Naito,et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone , 1998, Cancer Chemotherapy and Pharmacology.
[19] S. Loening,et al. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. , 1983, The Journal of urology.
[20] P. Whelan,et al. Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study. , 1995, British journal of urology.
[21] M. Parmar,et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) , 1988, British medical journal.
[22] C. Lee,et al. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. , 1989, The Journal of urology.
[23] K. Jauhiainen,et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. , 1996, The Journal of urology.
[24] K. Kurth,et al. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. , 1991, The Journal of urology.
[25] K. Jauhiainen,et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. , 1995, The Journal of urology.
[26] H. Huland,et al. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? , 1997, European Urology.
[27] Luc Bijnens,et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer , 1996 .
[28] J. Flamm,et al. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. , 1990, European urology.
[29] R Sylvester,et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cance , 1992, The Journal of urology.
[30] H. Huland,et al. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. , 1983, European urology.
[31] O. Dalesio,et al. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. , 1984, The Journal of urology.
[32] J. Witjes,et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. , 1998, The Journal of urology.
[33] G. Lunglmayr,et al. Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. , 1971, The Journal of urology.
[34] Richie Jp. Intravesical chemotherapy. Treatment selection, techniques, and results. , 1992 .
[35] L. Ose. L.D.L. AND TOTAL CHOLESTEROL IN CORD-BLOOD SCREENING FOR FAMILIAL HYPERCHOLESTEROLÆMIA , 1975, The Lancet.
[36] W. Catalona,et al. Urothelial Tumors of the Urinary Tract , 1992 .
[37] F. Longo,et al. Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. , 1969, The Journal of urology.
[38] M. Coleman,et al. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. , 1980, JAMA.
[39] P. Rigatti,et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. , 1998, Urology.
[40] H. C. Jones,et al. Thiotepa in the treatment of tumours of the bladder. , 1961, Lancet.
[41] F. Torti,et al. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. , 1991, Journal of the National Cancer Institute.
[42] R. Badalament,et al. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] Cynthia N. Batts. Adjuvant Intravesical Therapy for Superficial Bladder Cancer , 1992, The Annals of pharmacotherapy.
[44] F. D. da Silva,et al. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. , 1992, European urology.
[45] R. Badalament,et al. Treatment of superficial bladder cancer with intravesical chemotherapy. , 1997, Seminars in surgical oncology.
[46] D. Byar,et al. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. , 1977, Urology.
[47] B. Norlén,et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. , 1996, The Journal of urology.
[48] R Sylvester,et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. , 1993, The Journal of urology.
[49] C. Ed,et al. Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.
[50] J. Witjes,et al. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. , 1995, The Journal of urology.
[51] J. Flamm,et al. Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. , 1995, European journal of cancer.
[52] Huben Rp. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. , 1996 .
[53] R. Allman,et al. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. , 1997, British Journal of Cancer.
[54] W. Taylor,et al. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. , 1983, The Journal of urology.
[55] R Sylvester,et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. E , 1995, The Journal of urology.
[56] F. Micali,et al. Electromotive delivery of mitomycin C into human bladder wall. , 1997, Cancer research.
[57] M. Bibby,et al. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour , 1996, Cancer Chemotherapy and Pharmacology.
[58] S. Krege,et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. , 1996, The Journal of urology.
[59] R. Kinne,et al. Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. , 1996, The Journal of urology.
[60] B. Norlén,et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.